BAY 2666605

BAY 2666605

B647155-5mg

5mg

≥99%

-20°C储存

超低温冰袋运输

BAY 2666605 is an orally active PDE3A and PDE3B inhibitor with IC 50 s of 87 nM and 50 nM, respectively. BAY 2666605 is a PDE3A-SLFN12 complex inducer (WO2019025562A1; example 135) In Vitro BAY 2666605 (example 135) has anticancer effects, potently inhibit brain cancer(especially glioma, more specifically glioblastoma, astrocytoma), breast cancer (especially ductal carcinoma and adenocarcinoma), cervical cancer, AML(especially erythroleucemia), lung cancer(especially NSCLC adenocarcinoma and SCLC), skin cancer(especially melanoma), oesophagus cancer (especially squamous cell carcinoma), ovarian cancer, (especially teratocarcinoma, adenocarcinoma), pancreas cancer and prostatic cancer. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo BAY 2666605 (5 mg/kg; p.o; twice daily) teatment shows anti-tumor efficacy in murine xenotransplantation models of human cancer . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:PDE3A 87 nM (IC 50 ) PDE3B 50 nM (IC 50 )

BAY 2666605 是一种口服活性 PDE3A 和 PDE3B 抑制剂，其 IC 50 s 分别为 87 nM 和 50 nM。BAY 2666605 是一种 PDE3A-SLFN12 复合物诱导剂（WO2019025562A1；例 135）。

2275774-60-0

C17H12F4N2O2

352.28 g/mol

137465182

C[C@H]1C(=NNC(=O)O1)C2=CC(=C(C=C2)C3=CC=C(C=C3)F)C(F)(F)F

C[C@H]1C(=NNC(=O)O1)C2=CC(=C(C=C2)C3=CC=C(C=C3)F)C(F)(F)F

137465182

DMSO : 250 mg/mL (709.66 mM; Need ultrasonic)